ArticleNPJ digital medicine2023
Assessing overdiagnosis of fecal immunological test screening for colorectal cancer with a digital twin approach.
Article in NPJ digital medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Public (un)willingness to trade-off benefits and harms in decisions about cancer screening: A discrete choice experiment.Journal of medical screening · 2026Article
- Digital Twin Technology In Radiology.Journal of imaging informatics in medicine · 2026Review
- Reprogramming the gastrointestinal microenvironment with intelligent biomaterials and digital medicine: a perspective on precision intervention for digestive diseases.Frontiers in bioengineering and biotechnology · 2026Article
- Ethical and Quality of Care-Related Challenges of Digital Health Twins in Care Settings for Older Adults: Scoping Review.JMIR aging · 2025Article
- A scoping review of human digital twins in healthcare applications and usage patterns.NPJ digital medicine · 2025Article
- Adopting Non-invasive Approaches into Precision Colorectal Cancer Screening.Digestive diseases and sciences · 2025Review
- Balancing early detection and over-screening: Evaluating colonoscopy's role in shaping colorectal cancer trends in Korea.World journal of gastrointestinal oncology · 2025Article
- Definitions and Characteristics of Patient Digital Twins Being Developed for Clinical Use: Scoping Review.Journal of medical Internet research · 2024Article
- Article
- Digital twins for chronic lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Evolution of digital twins in precision health applications: a scoping review study.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Evaluating the magnitude of overdiagnosis associated with stool-based service screening for colorectal cancer (CRC) beyond a randomized controlled trial is often intractable and understudied. We aim to estimate the proportion of overdiagnosis in population-based service screening programs for CRC with the fecal immunochemical test (FIT). The natural process of overdiagnosis-embedded disease was first built up to learn transition parameters that quantify the pathway of non-progressive and progressive screen-detected cases calibrated with sensitivity, while also taking competing mortality into account. The Markov algorithms were then developed for estimating these transition parameters based on Taiwan FIT service CRC screening data on 5,417,699 residents aged 50-69 years from 2004 to 2014. Following the digital twin design with the parallel universe structure for emulating the randomized controlled trial, the screened twin, mirroring the control group without screening, was virtually recreated by the application of the above-mentioned trained parameters to predict CRC cases containing overdiagnosis. The ratio of the predicted CRCs derived from the screened twin to the observed CRCs of the control group minus 1 was imputed to measure the extent of overdiagnosis. The extent of overdiagnosis for invasive CRCs resulting from FIT screening is 4.16% (95% CI: 2.61-5.78%). The corresponding figure is increased to 9.90% (95% CI: 8.41-11.42%) for including high grade dysplasia (HGD) and further inflated to 15.83% (95% CI: 15.23-16.46%) when the removal adenoma is considered. The modest proportion of overdiagnosis modelled by the digital twin method, dispensing with the randomized controlled trial design, suggests the harm done to population-based FIT service screening is negligible.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.